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P h a s e  II T r ia l  o f  V in o r e lb in e  in M e ta s ta t ic  
S q u a m o u s  C ell  E so p h a g e a l  C arc in om a
By Thierry Conroy, Pierre-Luc Etienne, Antoine Adenis, D.J. Theo Wagener, Bernard Paillot, Eric Francois, 
Laurent Bedenne, Jacques-Henri Jacob, Jean-François Seitz, Harry Bleiberg, Christiane Van Pottelsberghe, 
Martine Van  Glabbeke, François-Michel Delgado, Solange Merle, and Jacques W ils for the European 
O rgan ization  for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
Purpose: To evaluate the response rate and toxic ef~ 
fects of vinorelbine (VNB) administered as a single agent 
in metastatic squam ous cell esophageal carcinoma.
Patients a nd  M ethods: Forty-six eligible patients with 
m easurable lesions were included and were stratified 
according to previous chemotherapy. Thirty patients 
without prior chemotherapy and 16 pretreated with cis- 
platin-based chemotherapy were assessable for toxicity 
and response. V N B  w as administered weekly as a 25- 
m g /m 2 short intravenous (IV) infusion.
Resuits: Six  of 30 patients (20%) without prior chemo­
therapy achieved a partial response (PR) (95% confi­
dence interval [Cl], 8%  to 39%), The median duration of 
response w as 21 weeks (range, 17 to 28). One of 16 
patients (6%) with prior chemotherapy had a complete 
response (CR) of 31 w eeks ' duration (95% Cl, 0%  to 30%)* 
The overall response rate (World Health Organization
CARCINOMA of the esophagus is responsible for approximately 300,000 deaths per year and ac­
counts for 4% of cancers worldwide.1 It is an uncommon 
tumor in the United States, accounting for 10,900 esti­
mated deaths in 1995,2 and adenocarcinoma now repre­
sents the major histologic type. However, squamous cell 
carcinoma is still common in China, Iran, and European 
countries, mainly France, Hungary, Ireland, Switzerland, 
the United Kingdom, and Portugal.1,3 Despite major ad­
vances in surgery and radiation therapy, the outcome for 
patients with squamous cell carcinoma of the esophagus
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[WHO] criteria) was 15% (CR, 2%; PR 13%; 95%  Cl, 6%  
to 29%). The median dose-intensity (DI) w as 20 m g/m 2/ 
wk. VNB was well tolerated and zero instances of W H O  
grade 4 nonhematologic toxicity occurred. At least one 
episode of grade 3 or 4 granulocytopenia w as seen in 
59% of patients. A  grade 2 or 3 infection occurred in 
16% of patients, but no toxic deaths occurred. Other side 
effects were rare, and peripheral neurotoxicity has been
minor (26% grade 1).
Conclusion: These data indicate that VNB  is an active 
agent in metastatic esophageal squamous cell carci­
noma. Given its excellent tolerance profile and low toxi­
city, further evaluation of VNB in combination therapy 
is warranted.
J Clin Oncol 14:164-170. © 1996 by American So ­
ciety of Clinical Oncology.
remains poor. In the registry of gastrointestinal tract tu­
mors established in the French County of Finistère/1 up 
to 70% of patients have advanced disease (stage T3 or 
T4 and node-positive lesions) and 13% have metastatic 
disease at diagnosis. The median survival time of 716 
patients with esophageal squamous cell carcinoma diag­
nosed from 1984 to 1988 was 9 months. Only 15% of 
the patients could be treated by curative resection, with 
a median survival time of 22.5 months.
Combined chemotherapy and radiation therapy repre­
sents a significant advance in locally advanced disease.5 
However, many patients develop local recurrence (17% 
to 67%) or distant métastasés (3% to 37%).5,h Autopsies 
of patients who die of esophageal cancer show that 51% 
to 82% have metastatic disease.7'9
A recent review outlined the results of single-agent 
chemotherapy for squamous cell carcinoma.10 Few drugs 
show evidence of response rates greater than 20%, but 
cisplatin, mitomycin, vindesine, and, more recently, pacli- 
taxel11 have activity at this level. Most clinical trials have 
been undertaken in small numbers of patients and some 
have also included patients with adenocarcinomas. Most 
trials include both locally advanced tumors and patients 
with metastatic disease, as well as a mixture of pretreated 
and untreated patients. Cisplatin is the most extensively 
tested drug,12"16 yielding a single-agent response rate of 
6% to 40%. Cisplatin combined with fluorouracil (5-FU) 
by continuous infusion is the most widely used chemo­
164 Journal of Clinical Oncology, Vol 14, No 1 (January), 1996: pp 164-170
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therapy for metastatic esophageal carcinoma. Using this 
combination, the European Organization for Research and 
Treatment of Cancer (EORTC) Gastrointestinal Tract 
Cancer Cooperative Group (GITCCG), in a randomized 
phase II trial, achieved a 36% response rate. In the cis- 
platin-only arm, the response rate was only 18%. How­
ever, toxicity was higher in the combination arm, there 
were 11% treatment-related deaths, especially from cere­
bral stroke, and no advantage in survival was seen.16
Vinorelbine (VNB; Navelbine, Pierre Fabre Oncologie, 
Boulogne, France) is a semisynthetic vinca alkaloid 
(5'nor-anhydro-vinblastine) that differs from other vinca 
alkaloids by a modification of the catharanthine moiety 
of the molecule.17 VNB causes disruption of microtubules 
by reversible binding to tubulin, which results in mitotic 
spindal dissolution and metaphase arrest in dividing cells.
Based on the results of the first phase I study,18 a 30- 
mg/m2 weekly bolus administration was recommended 
for phase II trials. Toxic effects in phase I and II studies 
have included myelosuppression, constipation, and phle­
bitis. Neurotoxicity greater than grade 2 is rare, but loss 
of deep-tendon reflexes is the most frequent event. VNB 
has demonstrated interesting levels of activity against 
breast carcinoma,19 non-small-cell lung cancer,20 and 
small-cell lung cancer.21 In most trials, the dose-intensity 
(DI) of VNB is 25 mg/m2/wk.
Our purpose was to evaluate in a phase II study the 
response rate, duration of response, and toxic effects of 
VNB in patients with metastatic squamous cell esopha­
geal carcinoma.
PATIENTS A N D  METHODS
The study reported here is a phase II trial of VNB given as a 
weekly intravenous (IV) infusion, conducted by the EORTC 
GITCCG.
Eligibility and Evaluation
Eligibility criteria for this study included the following: age less 
than 75 years; metastatic histologically proven squamous cell carci­
noma of the esophagus, previously untreated with any cytostatics 
or relapsing following first-line chemotherapy for locally advanced 
disease; World Health Organization (WHO) performance status <  
2 ; no chemotherapy within 12 weeks of study entry; at least one 
measurable lesion located outside of an irradiated area and dearly 
progressive; life expectancy greater than 3 months; peripheral neu­
ropathy <  grade 1 ; absolute granulocyte count > 2 X  10y/L; platelet 
count >: 100 X 109/L, hemoglobin level a  6.8 mmol/L; and adequate 
renal and hepatic function (serum creatinine, bilirubin, and alkaline 
phosphatase levels <  1.25 times upper limit of normal value). Exclu­
sion criteria were as follows: prior treatment with vinca alkaloids, 
absence of measurable disease, brain or leptomeningeal involvement, 
uncontrolled infection, presence of tracheal involvement, weight loss 
more than 20% based on usual weight, and previous radiation therapy
to the only measurable site of disease. Inclusion of patients with 
previous radiation therapy was allowed provided a target lesion was 
present outside the irradiated volume. Patients with previous head 
and neck carcinoma without recurrence could also be included if 
they had not received previous chemotherapy as part of the treatment 
of head and neck squamous cell carcinoma. All patients who entered 
the study gave oral or written informed consent according to policies 
followed by national legislations and to Helsinki regulations. The 
protocol was approved by ethics committees in France, Belgium, 
and the Netherlands.
Measurable disease was defined as a bidimensional tumor when 
measured with a ruler or calipers. Esophageal primary tumor was 
not considered as a measurable disease, but the response was also 
assessed in the primary tumor with barium swallow and computed 
tomographic (CT) scan. Patients with only malignant hepatomegaly 
were not eligible unless their disease was measured in two dimen­
sions by ultrasound or CT scan.
Pretreatment evaluation included physical examination, complete 
blood cell counts, platelet count, differential blood cell count, serum 
chemistry analysis, serum electrolytes, calcium, chest radiograph, 
barium swallow in patients with an intact primary tumor, tracheo­
bronchoscopy for cancer of the upper third, and liver ultrasound and/ 
or CT scan of the abdomen and chest (when indicated). Determina­
tions of complete blood cell counts, platelet counts, and creatinine 
level were to be performed weekly and serum chemistry analysis 
after at least every four injections. For response evaluation, barium 
studies, chest radiographs, and CT scan were repeated after every 8 
administrations.
Treatment
The starting dose of VNB was 25 mg/m2 in a 500-mL saline 
solution by 20-minute IV infusion on a weekly basis, For patients 
with histologically documented cirrhosis, the dose of VNB was re­
duced to 20 mg/m2/wk for the initial 4 weeks, then escalated to 25 
mg/m2/wk in all the subsequent cycles if the drug was well tolerated. 
VNB was given first through a peripheral vein; however, in case of 
injection pain or phlebitis, insertion of a central venous line was 
recommended. The prophylactic use of an antiemetic was not ad­
vised, but the prophylactic use oflaxatives (eg, lactulose) was recom­
mended. Concomitant irradiation to a field as small as possible was 
allowed for palliation if there was at least one other measurable 
lesion.
Response was assessed after 8 weeks of treatment. Responding 
patients were treated for at least 6 months or until disease progression 
or unacceptable toxicity. If a patient had stable disease (SD) after 
the first assessment, the investigator was free to decide whether or 
not to continue further VNB therapy. In patients with grade 2 periph­
eral neurotoxicity, the dose of VNB was reduced by 20%; patients 
with grade 3 peripheral neurotoxicity were withdrawn. Those pa­
tients who developed a paralytic ileus had VNB postponed until a 
normal bowel action occurred and further injections were given at 
a 50% dose reduction. Complete blood cell counts and serum creati­
nine level were repeated after every four administrations. VNB was 
withheld and the start of the next cycle delayed for 1 week until 
granulocyte and platelet counts were greater than 1 X 10‘J/L and 50 
X 109/L, respectively; subsequent doses were adjusted to tolerance.
Response and Toxicity Criteria
All eligible patients were considered assessable for toxicity and 
response (intent-to-treat analysis). Toxicity and response criteria
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w ere as defined according to W HO .22 Briefly, complete response 
(CR) was defined as the complete disappearance of all signs of active 
tumor and relief of all tumor-related symptoms; results had to be 
confirmed with a second evaluation at least 4 weeks later. Partial 
response (PR) was defined as a >  50% reduction in the sum of the 
products o f the longest diameters of measurable disease during two 
evaluations separated by an interval of 4 weeks without evidence of 
new lesions or progression of any lesion. SD was defined as no 
objective change, decrease less than 50%, or no increase of greater 
than 25% of the two greatest diameters of measurable iesions. Pro­
gressive disease (PD) was defined as any evidence of progression 
o f greater than 25% or the appearance of new lesions. Duration of 
responses was dated from  the start of treatment until progression. 
All responses were to be confirmed by external review. Overall 
su n  -val was measured from the beginning of therapy to death or 
cens >red at the date when the patient was last observed. DI was 
calcu ated for each patient from the total dose of VNB administered 
during the entire course o f treatment, and this expresses the mean 
drug cose in milligrams per square meter per week.
P atbn ts  were stratified before inclusion into two groups according 
to prior chemotherapy: patients with metastatic disease without any 
prior cnemotherapy and patients with metastatic disease after relapse 
following preoperative chemotherapy or chemoradiotherapy with or 
without subsequent esophagectomy. For each of the two groups, we 
used the sequential two-step statistical design of Gehan23 to compute 
the number o f patients required to detect a response rate == 20%, In 
the first step, 14 assessable patients had to be included, and if no 
responses were observed, the recruitment was discontinued. The 
probability of observing no response in these initial 14 patients is 
less than 0.05 if the actual response rate is ä  20%. If one response 
was observed in the first stage, one additional patient had to be 
included, and in cases in which there were two, three, or four re­
sponses in the first 14 patients, six, nine, or 11 additional assessable 
patients, respectively, had to be included.
RESULTS
Patient Characteristics
A total of 49 patients were enrolled between January 
1991 and December 1993. Three patients were ineligible 
for the following reasons: a single target lesion in a preir­
radiated area (one patient), uncontrolled hypercalcemia 
(one patient), and two lines of previous chemotherapy 
and grade 3 neurotoxicity at inclusion (one patient). No 
patient had palliative concomitant radiotherapy during 
treatment with VNB. Thus, data on response and toxicity 
are assessable for all eligible patients. Thirty patients had 
metastatic disease without any previous chemotherapy 
and 16 had metastatic disease after relapse following first- 
line chemotherapy (including preoperative chemotherapy 
and combined chemoradiotherapy). Previous chemother­
apy consisted in cisplatin-based regimens (with etoposide, 
n =  2; with 5-FU, n =  13; with 5-FU and carboplatin, n 
= 1), The median time between primary chemotherapy 
and study entry was 7 months (range, 2.8 to 34.6). Patient 
characteristics are listed in Table 1.
Table 1. Characteristics of Eligible Patients According
to Previous Chemotherapy
Variable
No Prior 
Chemotherapy
Prior
Chemotherapy
No. % No. %
No. of patients 30 100 16 100
Sex
Female 3 10 2 13
Male 27 90 14 87
Age, years
Median 60 55
Range 40-67 40-27
WHO performance status
0 5 17 5 31
1 18 60 8 50
2 7 23 3 19
Prior radiotherapy
No 20 67 2 13
Yes 10 33 14 87
Sites of disease
Primary tumor 24 80 4 25
Lymph nodes 18 60 5 31
Lung 9 30 11 69
Liver 12 40 6 37
Bone 6 20 1 6
Other 4 13 0 0
No. of metastatic sites
1 5 17 9 56
2 7 23 4 25
3 17 57 2 12
4 1 3 1 6
Toxicity
A total of 537 courses of VNB were given to 46 eligible 
patients. The median number of VNB administrations was 
eight (range, one to 53), The median DI was 20 mg/m2/ 
wk (range, 9 to 27). Three patients had cirrhosis and 
received a median dose of 16 mg/m2/wk (range, 15.8 to 
17.8).
VNB was well tolerated. However, one patient refused 
further therapy after one course because of neutropenia 
and grade 2 infection. No treatment-related deaths oc­
curred, Table 2 lists the maximum grades of hematologic 
toxicity for each patient. Most patients had dose reduc­
tions (65%) or delays (63%) for hematologic toxicity. 
One cirrhotic patient had a dose escalation after 4 weeks 
of treatment. During the whole treatment period, 27 pa­
tients (59%) had grade 3 or 4 granulocytopenia, but this 
was of short duration. The median nadir granulocyte 
count was 0.93 X  109/L (range, 0.02 to 13.75 X  109/ 
L). There' was no cumulative toxic effect. Hematologic 
toxicity was more severe in patients who had received
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Table 2. Highest W HO  Hematologic Toxicities According
to Previous Chemotherapy
Table 4. Neurotoxicity According to Previous Chemotherapy (%
Grade
Grade
Nadir
(WHO)
Variable
Prior
Chemotherapy
0 1 2 3 4
No. % No. % No. % No. % No. %
WBCs No 5 17 3 10 9 30 10 33 3 10
Yes
1
2 13 1 Ó 2 12.5 6 37.5 5 31
Neutrophils No 5 17 3 10 5 1Ó.5 14 46.5 3 10
Yes 2 12.5 1 6 3 19 6 37.5 4 25
Platelets No 30 100 0 0 0 0 0 0 0 0
Yes 13 82 1 6 1 & 1 6 0 0
Hemoglobin No 10 34 13 43 4 13 2 7 1 3
Yes 2 12.5 6 37.5 Ó 37.5 2 12.5 0 0
Toxic Effect Chemotherapy 0 1 2 3 4
Asthenia N o 57 30 10 3 0
Yes 69 19 12 0 0
Constipation No 80 10 10 0 0
Yes 75 6 6 13 0
Peripheral neurotoxicity No 80 20 0 0 0
Yes 62.5 37.5 0 0 0
treatment after one administration of VNB; these three 
patients were evaluated as having PD. Among the 30 
(25% grade 4 v 10%; P  = .21). Grade 3 or 4 anemia previously untreated patients, six (20%; 95% Cl, 8% to 
occurred in five patients (11%). There was no thrombocy- 39%) achieved a PR. Two patients had a PR not con- 
topenia in patients with first-line chemotherapy, but three firmed by a second evaluation and were considered to 
patients who had received previous chemotherapy had have SD; both refused further treatment and follow-up 
grade 1, grade 2, and grade 3 thrombocytopenia (respec- evaluation after initial documentation of response. If we
consider responses by site, two CRs of lung métastasés 
and one in node métastasés were observed. The sites of 
PRs were lymph nodes (four patients of 18 with metastatic 
nodes). Two patients also had a PR in the primary tumor, 
associated with a PR or CR in measurable metastatic
tively, during one course). Maximum nonhematologic and 
nonneurologic side effects per patient are listed in Table 
3. No grade 4 nonhematologic toxicity was reported.
Neurotoxicity was rare (Table 4): no peripheral neurop­
athy greater than grade 1 occurred. Six patients (20%)
with no prior chemotherapy and six (37.5%) with previ- disease. The median duration of response was 21 weeks 
ous chemotherapy had mild paresthesias (grade 1) or loss (range, 14 to 28).
of deep-tendon reflexes. Three patients had abdominal 
pain (one grade 2 with diarrhea, and two grade 3 associ­
ated with severe constipation).
Response to Therapy
All eligible patients are assessable for response (Table 
5). Two patients, one without and one with previous che­
motherapy, died early of pulmonary lymphangitis or he-
Of 16 patients with previous chemotherapy, one (6%; 
95% Cl, 0% to 30%) with late relapse (55 weeks) from 
primaiy chemoradiatxon had achieved a CR of pulmonary 
métastasés after nine VNB administrations. The duration 
of response was 31 weeks.
Responses were observed after a median of six courses 
(range, four to eight). At the time of analysis, four patients 
were still alive and 42 had died. The causes of death were
patic progression 9 and 16 days after first VNB adminis- PD (40 patients), cerebroischemic accident (one patient), 
tration, and another previously untreated patient refused and sudden death 6 weeks after PD (one patient). The
median survival time of the entire group was 6 months 
and does not differ for patients with or without previous
Table 3. Highest W HO  Nonhematologic and Nonneurologic Toxicity
Grade
chemotherapy.
Toxic Effect 
Variable
0 1
No. %  No. %  No. %  No. %  No. % Table 5. Clinical Response
Nausea/vomiting 29 66 9 20 4 9 2 5 0 0 No Prior Prior
Diarrhea 39 87 5 11 1 2 0 0 0 0 Overall Chemotherapy Chemotherapy
Liver toxicity 38 93 2 5 0 0 1 2 0 0 Variable No. % No. % No. %
Renal toxicity 43 96 2 4 0 0 0 0 0 0
Pulmonary toxicity 43 96 2 4 0 0 0 0 0 0 Eligible patients 46 100 30 100 16 100
Drug fever 40 89 4 9 1 2 0 0 0 0
U  1
CR 1 2 0 0 1
mb
6
Allerqy 44 98 1 2 0 0 0 0 0 0
13 0
<J f
Local reaction 38 85 3 7 2 4 2 4 0 0 PR 6 6 20 0
Cutaneous reaction 41 91 3 7 1 2 0 0 0 0 SD 16 35 11 3 7 5 31
Alopecia 38 85 5 11 1 2 1 2 0 0 PD 20 4 4 11 3 7 9 56
Infection 33 74 5 11 5 n 2 4 0 0 Early PD
Ä A A f t
1 2 1 3 0 0
Mucositis 39 87 4 9 2 4 0 0 0 0
Cardiotoxicity
T
44 98 . 0 0 1 2 0 0 0 0 Early death due to
Flu-like syndrome 42 93 3 7 0 0 0 0 0 0 malignant disease 2 4 1 3 1 6
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D ISC U SS IO N
This study was performed in patients with metastatic 
disease at diagnosis or relapse. This trial had a slow ac­
crual because of the rarity of occurrence of metastatic 
disease at diagnosis.3 Patients with locally advanced can­
cer were not eligible for this study, because rapid im­
provement of dysphagia can be obtained in 90% of pa­
tients, and local control in 60% of cases can be achieved 
with concurrent chemoradiotherapy.24 However, most es­
tablished regimens of chemotherapy, eg, 5-FU combined 
with cisplatin, have resulted in PR and CR rates of ap­
proximately 55%  to 60% for patients with locoregional 
disease and approximately 30% for patients with meta­
static disease.11 Few compounds have been tested as sin­
gle agents and the major drawback in early studies was 
the absence of strict response criteria, as well as the small 
number of patients, thus requiring the pooling of data 
from several studies. Mitomycin appeared to be an active 
agent, achieving a 42% response rate in the Eastern Coop­
erative Oncology Group (ECOG) study13 at the cost of 
prohibitive myelosuppression, but the response rate was 
lower in two other trials.25 Vindesine is also an active 
drug, yielding a 19% response rate in an overview of 
five compiled trials (25 responses among 129 assessable 
patients26'29), but peripheral neurotoxicity occurred in 
17% to 51% of the patients.26,28'29 Vinblastine and vincris­
tine, which are sometimes used in combination therapy, 
have never been tested as single agents. Cisplatin is prob­
ably the most active drug and has been tested in seven 
phase II studies with a response rate of 24% (56 responses 
among 231 patients10*12“16), but most of these trials in­
cluded both metastatic and locally advanced tumors. 
Moreover, in locally advanced tumors, the assessment of 
response cannot be performed using WHO criteria and 
evaluation of response remains difficult.10,30 Recently, 
paclitaxel followed by granulocyte colony-stimulating 
factor was tested in IS patients with locally advanced 
or metastatic squamous cell carcinoma, and five patients 
(28%; 95% Cl, 7% to 49%) achieved a PR.11
The results obtained with VNB are promising. We ob­
tained a 20% response rate in patients without prior che­
motherapy. All responses were confirmed by external re­
view. Responses were observed in all sites of disease, 
except liver. Two patients who showed unconfirmed PRs 
were evaluated as having SD, including one patient with 
a 55% decrease in a hepatic metastasis. Confirmation of 
this response was documented, but the observation was 
only continued for 2 weeks after the first PR assessment, 
because the patient refused further weekly treatment. We ■
>
strictly applied the WHO criteria and considered the re­
sponse to be SD. One of 16 patients with previous chemo­
therapy had a CR of 7 months’ duration. A preliminary 
report from the National Institute of Tumors of Milan 
recently confirmed the activity of VNB in squamous cell 
carcinoma of the esophagus with a different schedule.31 
They used a twice-monthly administration of 30 mg/m2 
and reported a response rate of 25% among 16 patients. 
PRs were achieved in one of six previously untreated and 
three of 10 previously treated patients. These results are 
consistent with the activity of VNB demonstrated in pa­
tients with recurrent or metastatic squamous cell carci­
noma of the head and neck.32,33
Although the results of a phase I study suggested that 
VNB should be given at 30 mg/m2 weekly, in phase II 
studies the DI usually ranges from 20 to 25 mg/m2. There­
fore, a weekly dose of 25 mg/m2 was selected for this trial, 
and even so, dose reductions and delays for hematologic 
toxicity resulted in a DI of 20 mg/m2/wk. Fifty-nine per­
cent of patients had grade 3 or 4 granulocytopenia, but 
this was rarely associated with infection; only 16% of 
patients experienced a grade 2 or 3 infection and no toxic 
deaths occurred. Hematologic toxicity was more severe 
in patients who had received previous chemotherapy. 
Granulocytopenia was the dose-limiting toxicity and led 
to dose reduction or delay in almost all patients.
Peripheral neuropathy has been infrequent (26% grade 
1), and this will allow further investigation of VNB, in 
combination with cisplatin. In contrast, vindesine neuro­
toxicity is a particular problem in patients with esophageal 
carcinoma treated with vindesine, cisplatin, and bleomy­
cin,10,34 with significant peripheral neuropathy seen in al­
most all patients who received more than four to six doses 
of vindesine,34 A randomized study conducted in stage 
III and IV non-small-cell lung cancer showed that grade
3 to 4 neurotoxicity occurred twice as frequently in the 
vindesine-cisplatin arm as in the VNB-cisplatin arm (33% 
v 15%; P <  .004).20
The results obtained with VNB are particularly encour­
aging in all respects: low toxicity, high response rate for 
a single agent, and at least comparable survival to other 
phase II regimens with active drugs such as cisplatin, 
vindesine, methotrexate, or 5-FIL The median survival 
time of patients with metastatic disease or recurrence 
treated with these agents was 2 to 3 months. I2“14,26,2K,3'<5 
The 6-month median survival time in this trial with a 
single agent is similar to that obtained with the complex 
drug combination of folinic acid (leucovorin), 5-FU, eto- 
poside, and cisplatin (FLEP) in patients with metastatic 
disease.36 Moreover, both experimental models in animals 
and extensive clinical data in non-small-cell lung card-
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noma show that addition of cisplatin to VNB may have a 
synergistic antitumoral effect without increased toxicity.20 
We are presently investigating within the EORTC 
GITCCG a combination of VNB and cisplatin in patients 
with metastatic esophageal squamous cell carcinoma. 
In conclusion, VNB has been identified as an active agent 
in metastatic squamous cell esophageal carcinoma. Further 
evaluation of this drug in combination therapy is warranted.
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